Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts
23 Enero 2024 - 7:00AM
Biognosys, a leader in next-generation proteomics solutions for
drug discovery and development, announced today the operational
readiness of its new proteomics facility in Massachusetts. This US
expansion facilitates access to select proteomics contract research
organization (CRO) services for our US biopharma customers.
The Massachusetts facility will initially focus on
TrueDiscovery® data-independent acquisition (DIA) discovery
proteomics services that offer biopharma researchers
high-throughput proteome profiling with industry-leading depth,
reproducibility, and cost-efficiency, powered by the Bruker timsTOF
mass spectrometry platform. Biognosys also anticipates offering
additional discovery and targeted proteomics services for US
customers to access domestically in the future.
“The opening of our new CRO facility in Massachusetts marks a
milestone in our commitment to making proteomics accessible
globally for life science research and drug development,” commented
Dr. Oliver Rinner, CEO and co-founder of
Biognosys. “We are excited to bring our CRO services
closer to our US customers and enable them to fully leverage the
potential of cutting-edge proteomics for the acceleration of
therapeutic discoveries, development and pharmacoproteomics.”
Dr. Rohan Thakur, President Life Sciences Mass
Spectrometry at Bruker, said: “Offering 4D-Proteomics CRO
services from the inventors of Spectronaut – the leading DIA
proteomics software, now augmented with deep learning – will
provide broader access to proteomics in key research areas such as
chemoproteomics, immunopeptidomics, or plasma proteomics.
Proteomics at the depth and scale of Biognosys’ TrueDiscovery
platform will accelerate insights into the complexity of disease
biology and is another step forward in the post-genomic era of drug
discovery and development.”
In the last 15 years, Biognosys has served US biopharma
companies from its facility near Zurich, pioneering the use of
next-generation DIA proteomics in drug research. By expanding its
presence near the life science cluster in the Boston-Cambridge
area, the company plans to extend its collaborations with
innovative early and late-stage biotech companies in New England
and across the Americas.
Biognosys’ laboratory at its headquarters in Switzerland remains
the company’s center of excellence for proteomics innovation and
offers Biognosys’ complete portfolio of services for discovery,
targeted, and structural proteomics to all regions including the
Americas:
- TrueDiscovery®
services for unbiased discovery proteomics from biofluids, tissues
and cells, with applications ranging from biomarker discovery to
mechanism of action studies, phosphorylation profiling, and
immunopeptidome profiling
- TrueSignature®
custom targeted proteomics panels for pharmacodynamic and clinical
biomarker monitoring through absolute protein quantification in
clinical trials
- TrueTarget®
services for novel drug target identification and validation
powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a
proprietary, patented chemoproteomics technology co-developed by
Biognosys
“Our dual-lab strategy underscores our dedication to providing
leading-edge, accessible proteomics solutions,” said
Biognosys’ Chief Officer of Scientific Operations (COSO),
Dr. Jakob Vowinckel. “The synergy between our Swiss and US
facilities allows us to serve diverse customer needs, fostering
innovation and collaborations.”
To offer customers industry-leading solutions for a wide range
of biological applications, Biognosys remains committed to
employing mass spectrometry instruments from multiple vendors in
their research services.
About
TrueDiscovery®
The Biognosys TrueDiscovery platform offers integrated
proteomics solutions across the entire drug development
pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM™)
mass spectrometry, an advanced Data Independent Acquisition
(DIA)-based protein quantification technology co-invented and
patented by Biognosys.
TrueDiscovery is the only platform that searches the complete
proteome to quantify thousands of the most relevant proteins,
including an unlimited number of proteoforms. The platform enables
the deepest unbiased profiling of tissue and biofluids proteomes
with unbeatable specificity on a large scale. The generated data
are highly reproducible and easily transferrable to clinical
assays. Studies can be performed in compliance with GCP guidelines.
For more information, visit truediscovery.bio.
About Biognosys
At Biognosys, we believe that deep proteome insights hold the
key to breakthrough discoveries that transform science for better
lives. With our versatile portfolio of next-generation proteomics
solutions, including the TrueDiscovery®, TrueTarget®, and
TrueSignature® research service platforms, our flagship software
Spectronaut®, and the PQ500™ kit, we make the proteome actionable
to empower research, drug development, and clinical
decision-making. Our solutions provide a multi-dimensional view of
protein expression, function, and structure in all biological
species and sample types. Our unique, patented technologies utilize
high-resolution mass spectrometry to quantify thousands of proteins
with industry-leading precision, depth, and throughput. Through our
strategic partnership with Bruker (Nasdaq: BRKR), we make
proteomics globally accessible. For more information, visit
biognosys.com.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5411f22b-cf51-4f28-823f-b275b58c4d70
https://www.globenewswire.com/NewsRoom/AttachmentNg/8a07139f-ded9-405e-b99d-31272a47946a
https://www.globenewswire.com/NewsRoom/AttachmentNg/6ac22376-012f-4152-9a94-a3126df69f9c
https://www.globenewswire.com/NewsRoom/AttachmentNg/111df067-42cb-477c-b6a4-6a8c92eb86a1
Media Contact
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 44 244 50 07
yves.serroen@biognosys.com
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De May 2023 a May 2024